Literature DB >> 19071004

Airflow obstruction and exercise.

Christopher B Cooper1.   

Abstract

The primary abnormality in chronic obstructive pulmonary disease (COPD) is chronic airway inflammation which results in airflow limitation. Disease progression is usually depicted as an accelerated decline in FEV(1) over time. However, COPD patients also manifest progressive static hyperinflation due to the combined effects of reduced lung elastic recoil and increased airway resistance. Superimposed on static hyperinflation are further increases in operational lung volumes (dynamic hyperinflation) brought on during exercise, exacerbations or tachypnea. An important consequence of exertional dyspnea is activity limitation. COPD patients have been shown to spend only a third of the day walking or standing compared with age-matched healthy individuals who spend more than half of their time in these activities. Furthermore, the degree of activity limitation measured by an accelerometer worsens with disease progression. COPD patients have been shown to have an accelerated loss of aerobic capacity (VO(2)max) and this correlates with mortality just as is seen with hypertension, diabetes and obesity. Thus physical inactivity is an important therapeutic target in COPD. Summarizing; airflow obstruction leads to progressive hyperinflation, activity limitation, physical deconditioning and other comorbidities that characterize the COPD phenotype. Targeting the airflow obstruction with long-acting bronchodilator therapy in conjunction with a supervised exercise prescription is currently the most effective therapeutic intervention in earlier COPD. Other important manifestations of skeletal muscle dysfunction include muscle atrophy and weakness. These specific problems are best addressed with resistance training with consideration of anabolic supplementation.

Entities:  

Mesh:

Year:  2008        PMID: 19071004     DOI: 10.1016/j.rmed.2008.10.026

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  25 in total

1.  Chronic obstructive pulmonary disease in China: the potential role of indacaterol.

Authors:  Jinming Gao; Niyati Prasad
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Effect of Yoga Breathing (Pranayama) on Exercise Tolerance in Patients with Chronic Obstructive Pulmonary Disease: A Randomized, Controlled Trial.

Authors:  David A Kaminsky; Kalpalatha K Guntupalli; Joan Lippmann; Stephanie M Burns; Melissa A Brock; Joan Skelly; Michael DeSarno; Heidi Pecott-Grimm; Ali Mohsin; Catherine LaRock-McMahon; Penney Warren; Martha C Whitney; Nicola A Hanania
Journal:  J Altern Complement Med       Date:  2017-07-17       Impact factor: 2.579

Review 3.  Executive summary: prevention of acute exacerbation of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Authors:  Gerard J Criner; Jean Bourbeau; Rebecca L Diekemper; Daniel R Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S Balter; Mohit Bhutani; Pat G Camp; Bartolome R Celli; Gail Dechman; Mark T Dransfield; Stanley B Fiel; Marilyn G Foreman; Nicola A Hanania; Belinda K Ireland; Nathaniel Marchetti; Darcy D Marciniuk; Richard A Mularski; Joseph Ornelas; Jeremy D Road; Michael K Stickland
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

4.  Relationship between sniff nasal inspiratory pressure and BODE index in patients with COPD.

Authors:  Leila Donária; Rafael Mesquita; Larissa Martinez; Luciana Sípoli; Josiane Marques Felcar; Vanessa Suziane Probst; Nidia Aparecida Hernandes; Fabio Pitta
Journal:  Lung       Date:  2014-10-01       Impact factor: 2.584

5.  Test Performance Characteristics of the AIR, GAD-7, and HADS-Anxiety Screening Questionnaires for Anxiety in Chronic Obstructive Pulmonary Disease.

Authors:  Anna M Baker; Janet T Holbrook; Abebaw M Yohannes; Michelle N Eakin; Elizabeth A Sugar; Robert J Henderson; Anne S Casper; David A Kaminsky; Alexis L Rea; Anne M Mathews; Loretta G Que; Joe W Ramsdell; Lynn B Gerald; Robert A Wise; Nicola A Hanania
Journal:  Ann Am Thorac Soc       Date:  2018-08

Review 6.  Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.

Authors:  Gerard J Criner; Jean Bourbeau; Rebecca L Diekemper; Daniel R Ouellette; Donna Goodridge; Paul Hernandez; Kristen Curren; Meyer S Balter; Mohit Bhutani; Pat G Camp; Bartolome R Celli; Gail Dechman; Mark T Dransfield; Stanley B Fiel; Marilyn G Foreman; Nicola A Hanania; Belinda K Ireland; Nathaniel Marchetti; Darcy D Marciniuk; Richard A Mularski; Joseph Ornelas; Jeremy D Road; Michael K Stickland
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

Review 7.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

8.  Disability and recovery of independent function in obstructive lung disease: the cardiovascular health study.

Authors:  Vincent S Fan; Emily R Locke; Paula Diehr; Anthony Wilsdon; Paul Enright; Sachin Yende; Mark Avdalovic; Graham Barr; Vishesh K Kapur; Rachel Thomas; Jerry A Krishnan; Gina Lovasi; Stephen Thielke
Journal:  Respiration       Date:  2014-09-09       Impact factor: 3.580

Review 9.  Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.

Authors:  Roland Buhl; Donald Banerji
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-10-26

Review 10.  Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Jiangna Han; Lu Dai; Nanshan Zhong
Journal:  BMC Pulm Med       Date:  2013-04-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.